DEF 14C: Rani Therapeutics Secures $60.3M, Revamps Governance

Rani Therapeutics Holdings, Inc. completed a $60.3 million private placement and approved significant corporate governance changes, including reducing Class B voting power and eliminating stockholder written consent, to address financial needs and comply with Nasdaq rules.

Summary

• Rani Therapeutics Holdings, Inc. entered into a Purchase Agreement on October 16, 2025, for a private placement of securities, raising approximately $60.3 million in gross proceeds.
• The private placement involved the issuance of Class A Common Stock, Pre-Funded Warrants, and Common Warrants to institutional and an affiliated investor (Mir Imran, a board member).
• The company had only $4.1 million in cash and cash equivalents as of September 30, 2025, and faced substantial doubt about its ability to continue as a going concern without the private placement proceeds.
• Stockholder approval was required for the issuance of Warrant Shares to Institutional Investors due to Nasdaq Listing Rule 5635(d), as the effective price was less than the Minimum Price and the potential issuance exceeded 20% of outstanding common stock.
• On November 24, 2025, InCube Labs, LLC, the Majority Holder (holding approximately 65.5% of voting power), approved the Warrant Share Issuances and an Amended and Restated Certificate of Incorporation by written consent.
• Key governance changes in the Restated Certificate include reducing Class B Common Stock voting power from 10 votes per share to one vote per share, eliminating stockholders' ability to act by written consent, and introducing additional stockholder protective provisions.
• The Restated Certificate also makes the company subject to Section 203 of the DGCL, which prohibits business combinations with interested stockholders for three years, and requires a supermajority (two-thirds) stockholder vote for certain amendments to bylaws and specific certificate sections.
• Special meetings of stockholders can now only be called by the Board, the chairperson of the Board, or the chief executive officer.
• The provision for a classified board of directors was eliminated, meaning directors will be elected for one-year terms.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the company successfully secured critical funding to avert an immediate 'going concern' risk. However, this comes with significant dilution for existing shareholders and substantial changes to corporate governance, reflecting a necessary but costly measure to ensure survival rather than a position of strength.

Positives

• Successfully raised approximately $60.3 million in gross proceeds through a private placement, addressing immediate liquidity concerns.
• The capital raise mitigates the substantial doubt regarding the company's ability to continue as a going concern, as explicitly stated in the filing.
• Compliance with Nasdaq Listing Rule 5635(d) was achieved through stockholder approval, ensuring continued listing eligibility.

Negatives

• The company's cash and cash equivalents were critically low at $4.1 million as of September 30, 2025, indicating significant financial distress prior to the capital raise.
• Existing stockholders will incur dilution of their percentage ownership to the extent that investors exercise the Common Warrants, which can purchase up to 125,000,004 shares of Class A Common Stock.
• The reduction of Class B Common Stock voting power from 10 votes to one vote per share significantly diminishes the voting influence of Class B holders.
• Elimination of stockholder action by written consent and new supermajority voting requirements for certain actions could make it more difficult for stockholders to influence corporate decisions or effect changes in management.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern without the proceeds from the Private Placement.
• Anticipate continued operating losses, requiring the company to continue raising funds through equity or debt offerings, or strategic transactions, to meet financial needs.
• Dilution of existing stockholders' percentage ownership upon the exercise of Common Warrants by investors.
• The investors, particularly the Majority Holder, could significantly influence future company decisions due to their substantial beneficial ownership.
• New governance provisions in the Restated Certificate could discourage or make it more difficult to accomplish a proxy contest or other change in management or acquisition of control by a substantial stockholder.

Future Outlook

The company anticipates continued operating losses and expects to continue raising funds through equity or debt offerings, or strategic transactions, to meet its financial needs. The Common Warrants will be exercisable for five years following the effective date of stockholder approval, and the Restated Certificate is expected to be filed on or about December 31, 2025.

Management Comments

• Our board of directors determined to pursue stockholder action by majority written consent of those shares entitled to vote in an effort to reduce the costs and management time required to hold a meeting of stockholders and to implement the above actions in a timely manner.

Industry Context

This filing does not provide specific industry context or trends, focusing solely on the company's internal financial and governance actions.

Corporate Governance

Related Party Transactions

• Mir Imran, a member of the company's Board of Directors and the sole managing member of InCube Labs, LLC (the Majority Holder), participated in the Private Placement.
• Mir Imran purchased 2,083,334 shares of Class A Common Stock and Common Warrants to purchase 2,083,334 shares of Class A Common Stock at a price of $0.605 per share.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the potential exercise of Common Warrants. Their ability to influence corporate actions through written consent is eliminated, and Class B voting power is reduced. However, the capital raise prevents immediate financial collapse.
• Employees: The capital raise ensures the company's continued operation, providing stability for employees.
• Creditors: The improved liquidity position from the capital raise reduces immediate credit risk.
• Management/Board: The governance changes, while reducing the Majority Holder's disproportionate voting power, also introduce provisions that could entrench current management by making proxy contests and changes of control more difficult.

Next Steps

• The actions approved by written consent will become effective 20 calendar days after the Information Statement is first mailed (on or about December 10, 2025).
• Commencing on the 21st calendar day after mailing, investors will be able to exercise the Common Warrants.
• The company expects to file the Restated Certificate with the Secretary of State of the State of Delaware on or about December 31, 2025.

Key Dates

Recommendation

The company has averted an immediate 'going concern' crisis by securing $60.3 million in capital. This is a critical positive, preventing potential insolvency. However, the capital raise comes at a significant cost, including substantial dilution for existing shareholders and a restructuring of corporate governance that centralizes control and limits shareholder activism. The company also explicitly states it anticipates continued operating losses and will need to raise more funds in the future. Given the mixed signals – immediate survival secured but long-term profitability and shareholder value creation still highly uncertain with ongoing dilution risk – a 'hold' recommendation is appropriate. Investors should monitor future financial performance and the impact of the governance changes.

Keywords

Rani Therapeutics, Private Placement, SEC Filing, DEF 14C, Capital Raise, Corporate Governance, Stockholder Approval, Nasdaq Listing Rules, Warrants, Dilution, Going Concern, Class A Common Stock, Class B Common Stock, Certificate of Incorporation